Induction of tumor regression in experimental model of human head and neck cancer by human a‐lak cells and IL‐2
- 12 March 1991
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 47 (5), 784-791
- https://doi.org/10.1002/ijc.2910470527
Abstract
In a nude mouse model of human squamous‐cell carcinoma of the head and neck (SCCHN), locoregional therapy with interleukin 2 and human lymphokine‐activated killer (LAK) cells resulted in a significant inhibition of growth of 3‐day established tumors. The same model was used for therapy of 7‐day established tumors with highly enriched populations of human adherent (A)‐LAK (CD3− CD56+) cells and IL‐2. Peritumoral transfer of 10 × 106 A‐LAK cells, whose in vitro cytotoxicity against a SCCHN cell line (PCl‐1) was not significantly different from that of LAK cells, resulted in complete regression of all 3‐day or 7‐day human SCCHN in nude mice. An initial inflammatory‐type reaction, which appeared within hours of the first peritumoral cell transfer, was accompanied by infiltration initially by granulocytes and plasma cells, and later by mononuclear cells into the tumor stroma. A‐LAK cells labelled with a fluorescent dye prior to injection appeared in the tumor stroma within 24 hr and were localized around or in the basal epithelial tumor layer by 48 hr. Histologic sections revealed an increasing epithelial disorganization and progressively decreasing basal epithelial layer, which were proportional to the increasing number of A‐LAK cells transferred. Within 4 weeks, the tumors were reduced to amorphous keratinic remnants surrounded by the connective tissue containing abundant mononuclear cells. Local administration of human A‐LAK cells and IL‐2 to SCCHN tumors growing in nude mice led to accelerated tumor differentiation, keratinization and regression.Keywords
This publication has 15 references indexed in Scilit:
- Preferential Localization of Human Adherent Lymphokine-Activated Killer Cells in Tumor MicrocirculationJNCI Journal of the National Cancer Institute, 1991
- Antiproliferative Effects of Cytokines on Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 1991
- Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assayJournal of Clinical Laboratory Analysis, 1990
- Stable cell membrane labellingNature, 1989
- The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2Annals of Surgery, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activityJournal of Clinical Immunology, 1981